Targeted Therapy With Immunoconjugates for Multiple Myeloma [PDF]
Frontiers in Immunology, 2020 The introduction of proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has markedly increased the survival of multiple myeloma (MM) patients. Also, the unconjugated monoclonal antibodies (mAb) daratumumab (anti-CD38) and elotuzumab (anti-SLAMF7)
Wassilis S C Bruins +2 more
exaly +6 more sources
The development of immunoconjugates for targeted cancer therapy [PDF]
Nature Reviews Clinical Oncology, 2014 Immunoconjugates are specific, highly effective, minimally toxic anticancer therapies that are beginning to show promise in the clinic. Immunoconjugates consist of three separate components: an antibody that binds to a cancer cell antigen with high ...
Brandon G Smaglo +2 more
exaly +4 more sources
Frontiers in Pharmacology, 2022 Immune checkpoint mechanisms are important molecular cell systems that maintain tolerance toward autoantigens in order to prevent immunity-mediated accidental damage.
Andrea Zanello +4 more
doaj +2 more sources
Molecular Oncology, 2019 Directing selective complement activation towards tumour cells is an attractive strategy to promote their elimination. In the present work, we have generated heteromultimeric immunoconjugates that selectively activate the complement alternative pathway ...
Carole Seguin‐Devaux +8 more
doaj +2 more sources
CD30-targeting immunoconjugates and bystander effects [PDF]
Nature Reviews Clinical Oncology, 2015 Shigeo Masuda +2 more
exaly +4 more sources
Decoding the Factor H-Related Proteins: Gatekeepers of Complement Dysregulation in AMD. [PDF]
Eur J ImmunolThis review will explore the role of the factor H‐related (FHR) proteins in age‐related macular degeneration (AMD), their accumulation in the outer blood/retinal barrier, and how they may contribute to barrier dysfunction and inflammation. ABSTRACT Age‐related macular degeneration (AMD) is the third most common form of blindness in the Western world ...
Tang J, Zgoda N, Clark SJ.
europepmc +2 more sources
Ribosome-Inactivating Proteins from Salsola soda L. and Saponaria officinalis L. Are Promising Candidates for Targeted Therapy of Colon Cancer [PDF]
BiomedicinesBackground/Objectives: Ribosome-inactivating proteins (RIPs) are plant-derived enzymes with potent cytotoxic activity, widely studied as anticancer agents, particularly as toxic payloads in immunoconjugates. Despite numerous encouraging results reported,
Francesco Biscotti +8 more
doaj +2 more sources
Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates. [PDF]
PLoS ONE, 2012 BACKGROUND: Anti-HIV immunoconjugates targeted to the HIV envelope protein may be used to eradicate the latent reservoir of HIV infection using activate-and-purge protocols.
Ryan B Craig +3 more
doaj +2 more sources
Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives
Biomedicines, 2018 Osteosarcoma (OS) is an aggressive osteoid-producing tumor of mesenchymal origin, which represents the most common primary bone malignancy. It is characterized by a complex and frequently uncertain etiology.
Daniele Mercatelli +2 more
exaly +2 more sources
Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
Nature Communications, 2019 Brain glioma treatment with checkpoint inhibitor antibodies to cytotoxic T-lymphocyte-associated antigen 4 (a-CTLA-4) and programmed cell death-1 (a-PD-1) was largely unsuccessful due to their inability to cross blood–brain barrier (BBB).
Anna Galstyan +20 more
doaj +2 more sources